# Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

> **NCT01312337** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 92 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** salvage iressa

## Key facts

- **NCT ID:** NCT01312337
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-09
- **Primary completion:** 2012-08
- **Final completion:** —
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2011-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312337, "Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01312337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*